DoH Policies screened during the period: 1 July 2021-30 September 2021
Date published:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact
Documents
- Elective Care Framework (PDF 1014KB)
- NICE Technology Appraisal TA706 - Ozanimod for treating relapsing-remitting multiple sclerosis (PDF 512KB)
- NICE Technology Appraisal TA707 - Nivolumab for previously treated unresectable advanced oesophageal cancer (PDF 513KB)
- NICE Technology Appraisal TA708 – Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis (PDF 511KB)
- NICE Technology Appraisal TA709 – Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (PDF 513KB)
- NICE Technology Appraisal TA710 – Ravulizumab for treating atypical haemolytic uraemic syndrome (PDF 513KB)
- NICE Technology Appraisal TA711 – Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (PDF 517KB
- NICE Clinical Guideline NG154 - Neonatal parenteral nutrition (PDF 517KB)
- NICE Clinical Guideline NG155 - Tinnitus: assessment and management (PDF 513KB)
- NICE Technology Appraisal TA713 – Nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer (CDF review TA484) (PDF 513KB)
- NICE Technology Appraisal TA712 – Enzalutamide for treating hormone-sensitive metastatic prostate cancer (PDF 511KB)
- NICE Technology Appraisal TA715 – Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed (partial review of TA375).(PDF 519KB)
- NICE Clinical Guideline NG156 - Abdominal aortic aneurysm: diagnosis and management (updates and replaces TA167) (514KB)
- NICE Clinical Guideline NG157 - Joint replacement (primary): hip, knee and shoulder (PDF 512KB)
- NICE Technology Appraisal TA719 – Secukinumab for treating non-radiographic axial spondyloarthritis (PDF 512KB)
- NICE Technology Appraisal TA718 – Ixekizumab for treating axial spondyloarthritis (PDF 514KB)
- NICE Clinical Guideline NG158 - Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (updates and replaces CG144) (PDF 518KB)
- NICE Technology Appraisal TA716 – Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (PDF 512KB)
- NICE Clinical Guideline NG181 - Rehabilitation for adults with complex psychosis (PDF 512KB)
- NICE Clinical Guideline NG180 - Perioperative care in adults (PDF 514KB)
- NICE Technology Appraisal TA721 – Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (PDF 623KB)
- NICE Technology Appraisal TA722 – Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (PDF 513KB)
- NICE Clinical Guideline NG198 - Acne vulgaris: management (PDF 516KB)
- NICE Clinical Guideline NG185 - Acute coronary syndromes (updates and replaces CGs 172, 167, 130, 94 and TA230) / (partially updates TAs 152 & 71) (PDF 529KB)
- NICE Technology Appraisal TA723 - Bimekizumab for treating moderate to severe plaque psoriasis (PDF 514KB)
- NICE Technology Appraisal TA720 - Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma (PDF 622KB)
- The Future Planning Model Project for Northern Ireland (PDF 571KB)
- Subordinate legislation amendments: The Safeguarding Board for Northern Ireland (Membership, Procedure, Functions and Committee) Regulations (Northern Ireland) 2012 (the SBNI 2012 Regulations) (PDF 7982KB)
- Family Practitioner Services Independent Appeals (PDF 553KB)